[go: up one dir, main page]

HK40065799A - Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders - Google Patents

Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders Download PDF

Info

Publication number
HK40065799A
HK40065799A HK62022054997.1A HK62022054997A HK40065799A HK 40065799 A HK40065799 A HK 40065799A HK 62022054997 A HK62022054997 A HK 62022054997A HK 40065799 A HK40065799 A HK 40065799A
Authority
HK
Hong Kong
Prior art keywords
dimethyltryptamine
dmt
meo
methoxy
compositions
Prior art date
Application number
HK62022054997.1A
Other languages
Chinese (zh)
Inventor
T·特尔维
Original Assignee
Gh研究爱尔兰有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gh研究爱尔兰有限公司 filed Critical Gh研究爱尔兰有限公司
Publication of HK40065799A publication Critical patent/HK40065799A/en

Links

HK62022054997.1A 2019-02-22 2020-02-24 Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders HK40065799A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19158806.0 2019-02-22

Publications (1)

Publication Number Publication Date
HK40065799A true HK40065799A (en) 2022-08-05

Family

ID=

Similar Documents

Publication Publication Date Title
IL285539A (en) Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
EP3927337B8 (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
IL288617A (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
EP3166648A4 (en) Compositions and delivery methods for treating dental infections, inflammation, sensitivity, and for use in dental restorations
CA2770066C (en) Prostacyclin, analogue or derivative thereof for the treatment of cystic fibrosis
WO2012158672A3 (en) Compounds for use in treatment of mucositis
GB202018908D0 (en) Compositions and methods for treating and preventing muscular disorders and dystrophies, steroid side effects, and inflammation
HUE066375T2 (en) 17-oximes of 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-ones for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
EP3927375A4 (en) Compositions for disease treatment
HK40065799A (en) Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
HK40107577A (en) 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
TWI906211B (en) Pharmaceutical compositions for use in treating pain
IL315894A (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
EP3860587A4 (en) Compositions comprising cbd for treating mental disorders
WO2016025533A3 (en) Compositions and methods for treating synucleinopathies
HK40104752A (en) Potassium-binding agents for use in hemodialysis patients
HK40020517A (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
EP3960143A4 (en) Treatment table
HK40102350A (en) Compounds for use in treating kidney disorders
HK40067656A (en) Potassium-binding agents for use in hemodialysis patients
HK40030323A (en) Pyruvate kinase activators for use in treating blood disorders
HK40040900B (en) Compounds for use in treating kidney disorders
AU2016902636A0 (en) Burneez, waterless first Aid treatment for minor burns.
WO2015195922A8 (en) Compounds for use in treating acute coronary syndrome and related conditions